Treatment-resistant schizophrenia and DAT and SERT polymorphisms

Gene

Volumn 543, Issue 1, 2014, Pages 125-132

  Bilic, Petar ^a   Jukic, Vlado ^a   Vilibic, Maja ^a   Savic, Aleksandar ^a   Bozina, Nada ^b  

^a Psychiatric Hospital Vrap e   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

DAT; SERT; Treatment resistant schizophrenia; VNTR

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; SEROTONIN; SEROTONIN TRANSPORTER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT RESISTANT SCHIZOPHRENIA;

DAT; SERT; TREATMENT-RESISTANT SCHIZOPHRENIA; VNTR;

ADULT; ANTIPSYCHOTIC AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG RESISTANCE; FEMALE; HUMANS; INDEL MUTATION; MALE; MIDDLE AGED; MINISATELLITE REPEATS; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84899629770     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.03.050     Document Type: Article

References (65)

1. Abi-Dargham A., et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. The American Journal of Psychiatry 1998, 155(6):761-767.
2. Arborelius L., et al. The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedeberg's Archives of Pharmacology 1993, 347(4):353-362.
3. Bannon M.J., et al. The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. European Neuropsychopharmacology 2001, 11(6):449-455.
4. Bonvicini C., et al. Serotonin transporter gene polymorphisms and treatment-resistant depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34(6):934-939.
5. Borowski T.B., Kokkinidis L. The effects of cocaine, amphetamine, and the dopamine D1 receptor agonist SKF 38393 on fear extinction as measured with potentiated startle: implications for psychomotor stimulant psychosis. Behavioral Neuroscience 1998, 112(4):952-965.
6. Bozina N., et al. Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. Journal of Psychopharmacology 2007, 21(7):728-734.
7. Bozina N., et al. Suicide ideators and attempters with schizophrenia-the role of 5-HTTLPR, rs25531, and 5-HTT VNTR Intron 2 variants. Journal of Psychiatric Research 2012, 46(6):767-773.
8. Breier A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America 1997, 94(6):2569-2574.
9. Carvelli L., Blakely R.D., DeFelice L.J. Dopamine transporter/syntaxin 1A interactions regulate transporter channel activity and dopaminergic synaptic transmission. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(37):14192-14197.
10. Cipriani A., Boso M., Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews 2009, 3:CD006324.
11. Conley R.R., Buchanan R.W. Evaluation of treatment-resistant schizophrenia. Schizophrenia Bulletin 1997, 23(4):663-674.
12. Davis K.L., et al. Dopamine in schizophrenia: a review and reconceptualization. The American Journal of Psychiatry 1991, 148(11):1474-1486.
13. Dean B., et al. Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behavioural Brain Research 1996, 73(1-2):169-175.
14. D'Souza U.M., Craig I.W. Functional polymorphisms in dopamine and serotonin pathway genes. Human Mutation 2006, 27(1):1-13.
15. Essock S.M., et al. Clozapine eligibility among state hospital patients. Schizophrenia Bulletin 1996, 22(1):15-25.
16. Excoffier L., Lischer H.E. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Molecular Ecology Resources 2010, 10(3):564-567.
17. Fan J.B., Sklar P. Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia. Molecular Psychiatry 2005, 10(10):928-938. (891).
18. Fiskerstrand C.E., Lovejoy E.A., Quinn J.P. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Letters 1999, 458(2):171-174.
19. Giros B., Caron M.G. Molecular characterization of the dopamine transporter. Trends in Pharmacological Sciences 1993, 14(2):43-49.
20. Goldstein J.M., et al. Effects of ICI 169,369, a selective serotonin2 antagonist, in electrophysiological tests predictive of antipsychotic activity. The Journal of Pharmacology and Experimental Therapeutics 1989, 249(3):673-680.
21. Guo S.W., Thompson E.A. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992, 48(2):361-372.
22. Guzey C., et al. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. European Journal of Clinical Pharmacology 2007, 63(3):233-241.
23. Heils A., et al. Allelic variation of human serotonin transporter gene expression. Journal of Neurochemistry 1996, 66(6):2621-2624.
24. Hernandez I., Sokolov B.P. Abnormal expression of serotonin transporter mRNA in the frontal and temporal cortex of schizophrenics. Molecular Psychiatry 1997, 2(1):57-64.
25. Hirsch S.R., Weinberger D.R. Schizophrenia 2003, xvi. Blackwell Science, Malden, Mass.; Oxford, (748 pp.). 2nd ed.
26. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophrenia Bulletin 2009, 35(3):549-562.
27. Hu X.Z., et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. American Journal of Human Genetics 2006, 78(5):815-826.
28. Huang S.Y., et al. Association of promoter variants of human dopamine transporter gene with schizophrenia in Han Chinese. Schizophrenia Research 2010, 116(1):68-74.
29. Jaccard J. Interaction effects in logistic regression. A Sage University Paper 2001, 07-135:70. Sage Publications, Thousand Oaks, Calif.; London.
30. Ji X., et al. Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population. Neuroscience Letters 2008, 435(2):95-98.
31. Kaiser R., et al. Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter. American Journal of Medical Genetics 2002, 114(3):323-328.
32. Kane J.M. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. The British Journal of Psychiatry. Supplement 1992, 17:41-45.
33. Kane J.M., Correll C.U. Past and present progress in the pharmacologic treatment of schizophrenia. The Journal of Clinical Psychiatry 2010, 71(9):1115-1124.
34. Kane J., et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988, 45(9):789-796.
35. Kleinbaum D.G. Logistic regression: a self-learning text. Statistics in the Health Sciences 1994, xiii. Springer, New York, (282 pp.).
36. Kohlrausch F.B., et al. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenetics and Genomics 2008, 18(7):599-609.
37. Lafuente A., et al. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophrenia Research 2007, 90(1-3):115-122.
38. Laruelle M., et al. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Archives of General Psychiatry 1993, 50(10):810-818.
39. Laruelle M., et al. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biological Psychiatry 1999, 46(1):56-72.
40. Lee H.Y., et al. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2009, 33(2):276-280.
41. Lesch K.P., et al. Isolation of a cDNA encoding the human brain serotonin transporter. Journal of Neural Transmission. General Section 1993, 91(1):67-72.
42. Lesch K.P., et al. Organization of the human serotonin transporter gene. Journal of Neural Transmission. General Section 1994, 95(2):157-162.
43. Liegeois J.F., et al. New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors. Journal of Medicinal Chemistry 2002, 45(23):5136-5149.
44. Lin Z., Uhl G.R. Human dopamine transporter gene variation: effects of protein coding variants V55A and V382A on expression and uptake activities. The Pharmacogenomics Journal 2003, 3(3):159-168.
45. Lucas G., Spampinato U. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. Journal of Neurochemistry 2000, 74(2):693-701.
46. MacKenzie A., Quinn J. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(26):15251-15255.
47. Malhotra A.K., et al. A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Molecular Psychiatry 1998, 3(4):328-332.
48. Martin J., et al. Mapping regulatory variants for the serotonin transporter gene based on allelic expression imbalance. Molecular Psychiatry 2007, 12(5):421-422.
49. McEvoy J.P., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry 2006, 163(4):600-610.
50. Mehler-Wex C., Riederer P., Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotoxicity Research 2006, 10(3-4):167-179.
51. Meltzer H.Y. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin 1992, 18(3):515-542.
52. Miller G.M., Madras B.K. Polymorphisms in the 3'-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Molecular Psychiatry 2002, 7(1):44-55.
53. Minabe Y., et al. Acute and repeated administration of the selective 5-HT(2A) receptor antagonist M100907 significantly alters the activity of midbrain dopamine neurons: an in vivo electrophysiological study. Synapse 2001, 40(2):102-112.
54. Potkin S.G., et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Molecular Psychiatry 2003, 8(1):109-113.
55. Praschak-Rieder N., et al. Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biological Psychiatry 2007, 62(4):327-331.
56. Slatkin M., Excoffier L. Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm. Heredity (Edinburgh) 1996, 76(Pt 4):377-383.
57. Suzuki T., et al. Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophrenia Research 2011, 133(1-3):54-62.
58. Szekeres G., et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2004, 124B(1):1-5.
59. Tsai S.J., et al. Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophrenia Research 2000, 44(3):177-181.
60. Vandenbergh D.J., Persico A.M., Uhl G.R. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Research. Molecular Brain Research 1992, 15(1-2):161-166.
61. Vazquez-Bourgon J., et al. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Research 2010, 175(3):189-194.
62. Wahlbeck K., et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. The American Journal of Psychiatry 1999, 156(7):990-999.
63. Xu M., et al. Pharmacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34(6):1026-1032.
64. Zhang A., et al. Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. Pharmacogenomics 2007, 8(10):1337-1345.
65. Zheng C., Shen Y., Xu Q. Association of intron 1 variants of the dopamine transporter gene with schizophrenia. Neuroscience Letters 2012, 513(2):137-140.